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Summary
The existence of at least three alleles of the HLA-DRB3 gene within the human population
is evident. These alleles express DRw52 determinants and react with monoclonal antibody (mAb)
7.3.19.1. The polymorphic epitope recognized by 7.3 .19.1 is not only present on human cells
but is also expressed on chimpanzee (Pan troglodytes) classII-positive cells. The 7.3.19.1 determinant
already existed before speciation of man and chimpanzee, and is at least 5,000,000 yr old. Two-
dimensional gel electrophoresis demonstrated that the various HLA- and Patr-DRw52 molecules
that are reactive with 7.3.19.1 exhibit isoelectric point differences due to primary amino acid
heterogeneity, as was confirmed by sequencing data. Sequence comparison allowed us to map
the binding site ofmAb 7.3.19.1 to the a helix of the major histocompatibility complex (MHC)
class II DRB1 domain surrounding the antigen-binding cleft. Despite MHC sequence variation,
chimpanzee antigen-presenting cells can present antigen (purified protein derivative) to human
T cell lines and vice versa. Only the HLA- and Patr-DRw52 molecules were shown to function
as restriction elements for antigen presentation across this species barrier. It is concluded that
these particular restriction determinants probably have been conserved in evolution. The HLA
and Patr-DRw52 molecules represent alleles displaying polymorphism that has been selected for
in evolution. Such "biomutants" may thus be more useful to study the biological significance
of MHC molecules than MHC variants that have been generated by in vitro mutagenesis
experiments.
u~Jne of the requirements for activation of Th lympho-
cytes is the complex formation of TCRs with MHC
class II molecules that are loaded with selected antigen frag-
ments (1). Such Th cells recognize denatured or processed
antigen only in the context of self MHC class II structures,
a phenomenon known as MHC restriction (2, 3). The struc-
ture of the antigen-binding site of MHC class II molecules
has been predicted according to a model (4) based upon the
three-dimensional crystal structure of HLAA2 class I mole-
cules (5). Binding studies provided evidence that MHC class
II molecules have a single antigen-binding site (6) also named
the cleft or groove.
In man, three major types ofMHC class II molecules have
been characterized, namely HLADP, -DQ and -DR (7). Each
of them has the capacity of acting as restriction element for
antigen recognition by Th cells (8, 9). Class II molecules are
transmembrane glycoproteins composed of a H (u) and a L
(a) chain, both encoded by the MHC complex (10). The HLA
DP, -DO, and -DR subregions contain multiple genes (11).
The highest degree ofpolymorphism is observed for the HLA
DRB1, -DQAI, -DQBI, and -DPB1 genes, whereas the HLA
DPAi, -DRB3, and -DRB4 genes are clearly less polymorphic
(12-16). The HLADRA1 gene appears to be invariant (17) .
The majority of the polymorphic MHC class II residues are
clustered around the antigen-binding site, indicating that these
residues may influence the binding of selected antigen seg-
ments and interaction with the TCR complex.
The polymorphism of MHC class II molecules has been
studied with a wide variety of techniques and reagents. Es-
pecially, mAbs have been shown to be powerful reagents to
describe the heterogeneity of MHC class II molecules. For
example, mAb 7.3.19.1 has been reported to be reactive with
an HLADRw52 determinant present on HLADR3-, -DR5-,
and -DRw6-positive cells (18). Immunoprecipitation studies
showed that the 7.3.19.1 epitope is located on the gene prod-
ucts encoded by the HLADRBI and -DRB3 genes ofHLA-
DR3-positive cells, whereas it is only present on HLADRB3
molecules expressed by HLA-DR5 and -DRw6 haplotypes
(19-22). Three alleles have been defined at the HLADRB3
locus (23). The various types of 7.3 .19.1-reactive HLA-DR
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in antigen presentation (22, 24) and may also act as stimulus
for alloreactive T cells (25).
We report here that the epitope recognized by mAb 7.3.19.1
is not only present on human cells but is also expressed on
chimpanzee (P. troglodytes) peripheral blood cells. Thus, this
epitope predates speciation of man and chimpanzee and is
therefore at least 5,000,000 yr old (26). The MHC of the
chimpanzee has been namedMhc-Patr, according to a recent
proposal (27). The HLA and Patr-DRw52 molecules ana-
lyzed were found to exhibit isoelectric point (pI) differences
suggesting primary amino acid variation. Alignment ofhuman
and chimpanzee DR a chain sequences confirmed this se-
quence heterogeneity but also made it possible to pinpoint
the 7.3.19.1-binding site. The antigen presentation capacity
of the different HLA- and Patr-DRw52 molecules was tested
in MHC restriction assays. Some of the Patr- and HLA-DR
molecules reactive with 7.3.19.1 were shown to function as
restriction elements in antigen presentation to both human
and chimpanzee Th cells, indicating that the particular RDs
involved have been conserved in evolution.
Materials and Methods
Cells. PBMC were isolated from heparinized venous blood
samples obtained from humans and chimpanzees by lymphocyte
separation medium (Organon Teknika Corp., Durham, UK) den-
sity centrifugation (specific density, 1.077 g/ml). Cells were washed
three times with HBSS (Gibco Laboratories, Grand Island, NY)
and resuspended in RPMI 1640 (Gibco Laboratories) supplemented
with streptomycin (100 Ag/ml) and penicillin (100 U/ml) sup-
plemented with 10% FCS, obtained from Flow Laboratories, Inc.,
Paisley, Scotland.
Production ofRadiolabeled CellExtracts.
￿
HumanB lymphoblastoid
cells or PHAstimulated PBMC (10') obtained from chimpanzees
were labeled for 16 h at 37°C with 0.5 mCi'sS-methionine (1,000
Ci/mmol; New England Nuclear, Boston, MA). Radiolabeled cells
were washed twice with 10 ml RPMI 1640 (Gibco Laboratories)
supplemented with 0.1% BSA and subsequently lysed in a buffer
containing 10 mM Tris-HCI, 5 MM M9Cl2, 20 mM NaCl, 0.1
mM PMSF, and 1% NP-40 (BDH Chemicals, Poole, UK), pH 7.6.
Cell extracts were spun at 12,000 g for 15 min. Supernatants were
used for immunoprecipitation purposes.
mAbs.
￿
7.3 .19.1(IgG2b) recognizes a DRw52 determinant on
HLADR3-, -DR5-, and -DRw6-positive donor cells (18) . The
determinant detected by 7.3.19.1 is located on HLA-DRB3-encoded
gene products of HLA-DR3-, -DR5-, and -DRw6-positive cells,
whereas also HLADRBI gene products ofHLA-DR3-positive cells
express this epitope (18-22, 25).
mAb B8.11.2 (IgG2b) reacts with a DR framework structure
present on all types of HLADR molecules (21, 22), whereas
mAb SPVL3 (IgG2a) detects a framework structure on HLA-
DQ molecules (28, 29). PL15 (anti-DP monomorphic) was a kind
gift ofDr. R. Knowles, Sloan-Kettering Memorial Hospital, New
York (30).
Immunoprecipitation Assays andTwo-dimensional(2D) GelElectropho-
resis. The methods used for immunoprecipitation and neuramin-
idase treatment of the samples have been described in detail (31).
1 Abbreviations used in this paper: pl, isoelectric point; PPD, purified protein
derivative; RD, restriction determinant; 2D, two dimensional.
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2D gel electrophoresis was performed as described by Goyert et
al. (32).
Antigen Presentation.
￿
The methods used to generate antigen-
specific bulk T cell lines and to present purified protein derivative
(PPD) to such T cells by autologous and allogeneic PBMC or by
EBVtransformed B cells have been reported (33, 34). Briefly,
antigen-specific T cells (10') were cultured together with irradi-
ated PBMC (5 x 10') or with lymphoblastoid B cells (5 x 104)
and PPD, (10 Rg/ml) in 96-well flat-bottomed microtiter plates in
triplicate. Inhibition ofproliferative responses was achieved by the
addition ofmAb to the test system. As a control, nonimmune mouse
ascites was tested. All antibodieswere used in a final concentration
comparable with the ascites solution diluted 1 :100 or 1:200,which
represents an excess of antibody. Proliferation of lymphoblastoid
T cells was measured by ['I4)thymidine (6.7 Ci/mmol; Radio-
chemical Centre, Amersham International, Amersham, UK) in-
corporation. Means and SEMs ofthe means were computed from
the cpm of triplicate tests.
Results
2D-GelElectrophoresis ofMHCClassIIMolecules.
￿
Immu-
noprecipitation studies performed on human donor cells have
demonstrated the reactivity ofmAb 7.3.19.1 with HLADR3,
-DR5, and -DRw6 haplotype-encoded HLA-DRB3 gene
products and with HLADRBI gene products ofHLADR3-
positive cells (18-22, 35). At least three alleles of the HLA
DRB3 gene are found within the human population, named
HLADRB3*0101 (DRw52c), -DRB3*0201 (DRw52b), and
-DRB3*0301 (DRw52c), respectively (23, 36).
A panel of chimpanzee cells, RFLP typed for their Patr-
DR specificities (Bontrop et al., manuscript in preparation),
was screened for the presence of the 7.3.19.1-defined DRw52
epitope by conductingimmunoprecipitation studies followed
by 2D gel electrophoresis. All 65 chimpanzees tested were
found to be reactive with 7.3.19.1. Based upon electrophoretic
mobility, at least three different types ofPatr-DRw52 mole-
cules could be detected. As can be seen (Fig. 1), mAb 7.3.19.1
isolates one type ofPatr-DRw52 («0c) molecules in the case
of chimpanzee Ton, whereas two types of Patr-DRw52 (otRb
+ acfc) molecules are observed for the chimpanzee Lock.
Within the chimpanzee colony, at least one other Patr-DRw52
molecule with a distinct isoelectric point (pl) is present, desig-
nated Patr-DRw52 (cx0a) (data not shown). For control pur-
poses, 7.3.19.1 was also used to isolate HLADRw52 mole-
cules from the human cell line WVE, which is heterozygous
for its MHC region and types as HLADRw13-Dw19-DQw6,
-DRw8-DQw3 positive. Immunoprecipitation with 7.3.19.1
allows the isolation of the HLADRB3 *0301 (DRw52c) gene
product, which is found in strong linkage disequilibrium with
the HLADRw13-Dw19 specificity within the Caucasoid popu-
lation. HLADRw8-positive cells are knownto lack the HLA
DRB3 gene and express no gene product reactive with 7.3.19.1
(18, 21). 2D gel analysis showed that the pl of the HLA-
DRB3 *0301 (DRw52c) gene product is lying intermediate
between the two types of Patr-DRw52 (3 chains (Fig. 1).
None of the presently described Patr-DRw52 /3 chains were
found to share pIs with the HLADRB3 *0101 (DRw52c),
-DRB3 *0201 (DRw52b), and -DRB3*0301 (DRw52c) gene
products. Immunoprecipitation with mAb B8.11.2 provedFigure 1 . 2D gel elec-
trophoretic analysis of
neuraminidase-treated Patr-
DRw52 and HLA-DRw52
molecules isolated with mAb
7 .3.19 .1 from chimpanzee and
human cells. Patr-DRw52 mol-
ecules were isolated from the
chimpanzees Ton and Loek,
whereas HLA-DRw52c (HLA-
DRB3'0301) molecules were
isolated from the human B cell
line WVE. All samples were
run under identical conditions .
In addition to the class II a
and 0 chains, the position of
actin (A) has been marked .
that the Patr-DRw52 molecules reactive with 7.3.19.1 are
also bearing a 338.11.2-definedDR framework determinant
(Fig . 2) . In man too, it is known that the different HLA-
DRw52 molecules express both the 7.3.19.1 and 338.11.2 de-
terminant (18-22) .
The distribution of the different types of Patr-DRw52 class
II molecules among a selected panel ofchimpanzees used for
the present study has been summarized in the left part of
Table 1 .
Antigen Presentation Assays.
￿
It was investigated whether
Table 1 .
￿
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-, <5,000 cpm ; +, a range of 5.000-20,000 cpm ; + +, >20,000 cpm .
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Figure 2 .
￿
2D gel analysis of the (non-neuraminidase-treated) Ntr
class II molecules isolated from the chimpanzee cell line Hugo with
the mAb 338.11.2 . mAb 7.3.19.1 isolates only the Patr-DRw52 otoc
molecules. The position of actin (A) has been marked.
chimpanzeeAPC are able to present PPD to human antigen-
specificTh cells. Xeno-antigen presentation was not observed
using 10 chimpanzeeAPC representing five RFLP-determined
DR specificities in combination with HLADR1-, -DR2-,
-DR4, and -DR7-positiveTh cells (data not shown) . In con-
trast, successful antigen presentation by chimpanzeeAPC was
seen in combination withTh cells originating from the HLA
homozygous typing cell donors CAA (HLA-DR3-Dw24-
DQw2), HHK (HLADRw13-Dw18-DQw6), and the het-
erozygous individual WVE (HLA-DRw13-Dw19-DQw6,
-DRw8-DQw3) (Table 1) . Although chimpanzeeAPC could
present antigen to thesehuman PPD-specificTh cells, dAeren-
tial reactivity patterns were observed . As can be seen in Table
1 and Fig . 3, only four (Carolina, Lock, Ton and Hugo) of
Human Th Cell Proliferation
Chimpanzee APC
DR
RFLP
Patr-
DRw52
(2D)
Carolina 2,2 52c
Loek 2,4 52b,c
Ton 2,2 52c
Hugo 2,2 52c
Socrates 4,10 52b
Wodka 1,4 52b
Plato 4,10 52b
Nicoline 4,10 52b
Samson 4,5 52a,b
Ulla 5,10 52a,c
HHK
DRw52a
333'0101
CAA
DRw52a
B3'0101
QBL
DRw52b
B3'0201
WVE
DRw52c
B3'0301
ND - - + +
ND + - -cPMX10-3
50I
40
PPD 1/200
Figure 3 .
￿
Antigen presentation by chimpanzee APC to human
antigen-specific (PPD) Th cell line WVE . Loek, Ton, Hugo, Socrates,
Wodka, Nicoline, and Samson are chimpanzees, whereas M . L. is a
human control cell (HLA-DRw13-Dw19-DQw6 positive) . PHA in-
duced a proliferation of 93,000 ± 5,000 cpm, whereas proliferation
without antigen to medium was 1,000 ± 100 cpm.
the 10 tested chimpanzee APCs could present antigen to the
human T cell line WVE (HLADRw13-Dw19-DQw6,
-DRw8-DQw3) . A second cluster of reactivity was seen for
the Patr-DR5-positive cells that were found to present PPD
fragments toHHK and CAA antigen-specific Th cells (Table
1) . Both theHHK and CAA donor cells express the HLA-
DRB3*0101(DRw52a) gene product (Table 1) . Patr-DRw52a-
induced proliferation was not seen for QBL and WVE Th
cells (Table 1).
It was also tested whether humanAPC could present an-
tigen to chimpanzee T cells. To this purpose, PPD-specific
Th cells were generated from the chimpanzees Plato, Caro-
lina, and Loek . APC from the individual WVE were able
to present antigen to these chimpanzee Th cell lines . Tetanus
toxoid was used as a control antigen and did not induce Th
cell proliferation, whereas species-mismatched presentation
of PPD was observed for all three chimpanzee T cells lines
tested (Fig. 4) . The fact thatWVE APC can present antigen
to Plato PPD antigen-specific T cells, but that the reciprocal
situation (Table 1) is not observed, may be due to differences
in the T cell repertoire.
Inhibition of antigen-specific T cell proliferation was as-
sayed withmAbs to determine the type ofMHC class II mol-
ecules involved in antigen presentation across a species bar-
rier . Well-characterized mAbs, the reactivity patterns ofwhich
had been defined in immunoprecipitation assays, such as
7.3.19.1 (DRw52), B8.11.2 (DR-backbone), SPVL3 (DQ-
backbone), and PL15 (DR-backbone), were selected for inhi-
bition purposes . These antibodies had beenshown to precipi-
tate the corresponding Patr-class II region products in chim-
panzees too (Bontrop et al ., manuscript in preparation) .
Proliferation by antigen-specific Th cells ofWVE to PPD
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Figure 4 .
￿
Antigen presentation by human WVE APC to PPD
antigen-specific T cell lines obtained from the chimpanzees Plato,
Loek, and Carolina .
by APC from chimpanzee Loek was inhibited to the same
extent with the antibodies 7.3.19.1 (DRw52) and B8.11.2
(DR), whereas SPVL3 (DQ and PL15 (DP) did not inhibit
T cell proliferation (Fig . 5) . Similar inhibition patterns were
observed for the other combinations listed in Table 1, which
showed positive Th cell proliferation, emphasizing that the
Patr-DRw52 molecules are used as restriction elements .
Discussion
One ofthe milestones in recent immunology has been the
demonstration that T cells recognize degraded antigen seg-
ments in the context of self MHC, a phenomenon known
asMHC restriction. Consequently, antigen presentation to
antigen-specific Th cells is normally observed with autolo-
gous or with allogeneic APC sharing identical MHC mole-
cules. The present panel data show that also chimpanzeeAPC
can present antigen to human antigen-specific Th cells and
vice versa. Similar observations were made by Lechler et al.
(37), who described the species-mismatched presentation of
antigen by mouse I-E molecules to an HLADRI-positive
Figure 5 .
￿
Inhibition of antigen-specific proliferation with MHC
class II-specific mAbs of APC derived from chimpanzee and human
Th cells .influenza-specific Th clone, whereas Waters et al. (38) reported
antigen presentation by murine and human cells to a murine
T cell hybridoma. These data could be explained as degeneracy
of MHC restriction (37). On the other hand, species-mis-
matched restriction determinants that are functional in xeno-
antigen presentation assays more likely reflect the existence
of evolutionary preserved structures. Alleles containing such
preserved segments are probably encoded by ancestral haplo-
types or segments of such haplotypes (39).
Immunoprecipitation studies followed by gel electropho-
resis analyses showed that man and chimpanzee express iden-
tical epitopes on MHC class II molecules reactive with both
the mAbs 7.3.19.1 and B8.11.2 (Figs. 1 and 2). The various
HLA and Patr-DRw52-detected molecules display pI differ-
ences, even after neuraminidase treatment, suggestingheter-
ogeneity due to primary amino acid variation.. According to
the transspecies hypothesis of MHC polymorphism (40-42),
the evolution of MHC alleles does not start at the inception
of a species, but is rather a process in which a major group
of alleles is passed on in the phylogeny from one species to
another. Thus, the existence of the polymorphic 7.3.19.1 de-
terminant predates speciation of man and chimpanzee (26),
and therefore, this epitope is at least 5,000,000 yr old.
Antigen presentation across the species barrier between man
and chimpanzee was only observed with HLA or Patr-DRw52
molecules as antigen presenting structures (Figs. 3 and 5).
Antigen-specific Th cell proliferation couldbe inhibited with
the mAbs 7.3.19.1 (DRw52) and B8.11.2 (DR), but not with
SPVL3 (DQ) and PL15 (DP), pinpointing the Patr-DRw52
otoc molecules as the antigen-presenting structures. Th cells
derived from WVE should have TCRs educated to recog-
nize antigen fragments in the context of the HLADRB3*0301
(DRw52c) gene product, which is reactive with 7.3.19.1 (Fig.
10
HLA-
DRB1*0101 GDTRPRFLWQ
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DRB1*1101 --------EY
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V-y_______ -----F-D-Y
STS------- -----F-D-Y
STS------- -----F-D-Y
1). Particular WVE-TCR are not only able to recognize an-
tigen fragments presented by autologous MHC classII struc-
tures, but apparently also recognize PPD fragments in the
context of a Patr-DRw52 arc molecule. Patr-DR2-positive
cells were not able to present antigen to CAA-, HHK-, or
QBL-derived antigen-specific T cells that express other al-
leles at the HLA-DRB3 locus (Table 1).
Until now, no antigen presentation by chimpanzee APC
has been shown to HLADRB3*0201 (DRw52b) and -DRw52
epitope-negative HLA-DRBl-educated TCRs (Table 1). This
may be due to the fact that not enough combinations were
tested. Another explanation would be that the MHC-DRB1
restriction epitopes of man and chimpanzee have been con-
served in evolution to a' lesser extent than those oftheDRw52
determinant-positive MHC-DRB3 molecules. If the latter
explanation is true, this would suggest that MHC-DRw52
molecules have been successful in the regulation of an im-
mune response to the same type ofpathogens that are a threat
to distinct species.
Three different types of Patr-DR molecules expressed by
the chimpanzee Hugo have recently been sequenced (43). From
the Hugo cDNA library,, a clone designated C4-2 was iso-
lated that shares a high amount of sequence homology with
the human DRB3*0301 (DRw52c) gene but clearly is not
completely identical to its human equivalent. The corre-
sponding gene product of the Hugo C4-2 clone is most likely
reactive with mAb 7.3.19.1, and thus can be isolated by im-
munoprecipitation assays (Fig. 2) . To detect the putative
binding site of mAb 7.3.19.1, the amino acid sequences of
various HLA- and Patr-C4-2 DR (3 first domain sequences
were lined up (Fig. 6) according to a recentlypublished method
(44). As mentioned earlier, 7.3.19.1 detects a DRw52 deter-
minant present on HLA-DR3 haplotype-encoded DRBI and
60
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--N--- -----V---- ----
--N--- __________ ----
--N--- -----V---- ___-
Figure 6.
￿
Definition of the 7.3.19.1 epitope by comparison of different HLA- and Patr-DR /3 first domain sequences. The putative binding
site of mAb 7.3.19.1 has been boxed.
R_S------- ---_-Y_D_Y FH----FL__ __________ ______V__S ----------
--S------- -----F_--H FH----YA__ __________ R--------- ----------
__S------- -----F___H FH----YA__ ---------- R--------- -----------
__S------- -----F___Y FH----F___ ---------- ------V__S ____-____
V_S___-___ -----F___Y F-----Y___ ---------- __P___V__S ____-__-_-DRB3 gene products, whereas this epitope is exclusively lo-
cated on HLADR5 and -DRw6 haplotype-encoded DRB3
gene products (18-25). The unique reactivity pattern of
7.3.19.1 correlateswith the boxed motive KRG at amino acid
numbers 71-73 (Fig. 6). As would be expected, this motive
is also present on the C4-2 clone-derived amino acid sequence
from Hugo (Fig. 6). This KRG motive maps to the ce helix
section in the antigen-binding cleft of MHC class II mole-
cules (44).
APC derived from the chimpanzee Hugo can successfully
present antigen to WVE Th cells that have been educated
to see PPD in the context ofthe HLADRB3 *0301(DRw52c)
gene product. However, the Patr-C4-2 and HLADRB3*0301
gene products display amino acid sequence differences (Fig.
6), as already could be predicted based upon pl differences
detected after 2D gel electrophoresis (Fig. 1). Thus, amino
acid substitutions at positions 11, 32, 37, 53, and 85 within
the Patr-DRw52 tx0c molecules apparently do not interfere
with the presentation of PPD to a humanWVE-derived TCR
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